{"id":3109,"date":"2022-04-29T15:32:20","date_gmt":"2022-04-29T05:32:20","guid":{"rendered":"https:\/\/orthocell.com\/us\/?p=3109"},"modified":"2022-04-29T15:32:20","modified_gmt":"2022-04-29T05:32:20","slug":"quarterly-report-period-to-31-march-2022","status":"publish","type":"post","link":"\/americas\/quarterly-report-period-to-31-march-2022\/","title":{"rendered":"Quarterly Report | Period To 31 March 2022"},"content":{"rendered":"
Orthocell has today published its Quarterly Report for the period ended 31 March 2022.<\/p>\n
Standout achievements for this Quarter include:<\/strong><\/p>\n
\n
Remplir\u2122 nerve repair device receives Australian regulatory approval <\/strong>for introduction into the Australian nerve repair and regeneration market<\/li>\n
Application for inclusion of Remplir\u2122 on the Prostheses List on track<\/strong> for submission in Q2 CY2022<\/li>\n
Final Remplir\u2122 24 month results of all patients in the nerve regeneration study on track<\/strong> for Q2 CY2022<\/li>\n
SignificantStriate+\u2122 US market entry progress <\/strong>with sale of over 1,500 Striate+\u2122 units achieved, and commencement of facility upgrade to enable scale up Striate+\u2122 manufacturing capacity to >100,000 units per year<\/li>\n
Striate+\u2122 distributor discussions progressed <\/strong>and the Company is in advanced discussions to engage its first US distributor and establish Striate+\u2122 as the premium dental membrane<\/li>\n
The final data from the OrthoATI\u2122 Phase 2a study on track for Q2 CY2022<\/strong><\/li>\n<\/ul>\n